Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobramycin inhalation in acute exacerbation of bronchiectasis with Pseudomonas aeruginosa
ChiCTR2400081616Phase 4Not yet recruiting
- Sponsor
- Tri-Service General Hospital Songshan Branch
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in bronchiectasis and Pseudomonal infection comparing Tobramycin inhalation solution arm with Normal saline placebo arm (2 arms). Primary endpoint: Sputum Pseudomonas aeruginosa density change from baseline (primary). Planned start Mar 2024; status: not yet recruiting.
02
Drugs
tobramycin
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on ChiCTR2400081616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081616.